Lv1
90 积分 2025-07-31 加入
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
7个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
7个月前
已完结
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer
7个月前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
7个月前
已完结
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
8个月前
已完结
ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity
8个月前
已完结
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial
8个月前
已完结
Cardiotoxicity of Epirubicin Versus Doxorubicin: Cost and Clinical Results
9个月前
已关闭
Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
9个月前
已完结
Rare molecular subtypes of lung cancer
9个月前
已完结
皖公网安备34019202002308
